title: Clinical trials on adjuvant chemotherapy for breast cancer.
abstract: Clinical trial initiated in 1975 at the Petrov Research Institute of Oncology (Leningrad) included 1228 patients with breast cancer Stages I, II, and III. Adjuvant chemotherapy in patients with Stages I-II (P T0-2N0-1M0) leads to decrease in mortality rate by 24.3% in the case of monochemotherapy (thiotepa, six courses, 200 mg each course) and 32.4% in the case of polychemotherapy (thiotepa, methotrexate, 5-fluorouracil [TMF], cyclophosphamide, methotrexate, 5-fluorouracil [CMF], six course). There is a trend to higher (by 7.8%-9.8% versus control) rates of adjusted survival in the groups of patients with relatively early stages of breast cancer (P T0-2N0M0) subjected to adjuvant mono- and polychemotherapy. In the group of breast cancer patients (P T0-2N0-1M0) who received adjuvant polychemotherapy (TMF, CMF schemes) the survival rates are higher by 12.0%-16.6% than in the control group during the sixth, seventh, and eighth years of the follow-up. Favorable effect of adjuvant chemotherapy manifested by diminished mortality rate and prolonged survival was statistically significant only in the group of patients younger than 50 years.
authors.forename: V F
authors.initials: VF
authors.lastname: Semiglazov
authors.forename: J L
authors.initials: JL
authors.lastname: Bavli
authors.forename: V M
authors.initials: VM
authors.lastname: Moiseyenko
authors.forename: S V
authors.initials: SV
authors.lastname: Rzhankov
authors.forename: N S
authors.initials: NS
authors.lastname: Migmanova
authors.forename: R T
authors.initials: RT
authors.lastname: Popova
authors.forename: I K
authors.initials: IK
authors.lastname: Seleznyov
authors.forename: B V
authors.initials: BV
authors.lastname: Kremen
authors.forename: T V
authors.initials: TV
authors.lastname: Kostetskaya
authors.forename: N J
authors.initials: NJ
authors.lastname: Barash
mesh_terms: D000328:Adult; D000367:Age Factors; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008408:Mastectomy; D008875:Middle Aged; D009362:Neoplasm Metastasis; D013852:Thiotepa / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D013852:Thiotepa